Bradmer Pharmaceuticals Inc. (Bradmer) is a Canada-based life sciences company focused on developing drugs to treat cancer. Bradmer focused on the treatment of glioblastoma multiforme (GBM), a form of primary brain cancer. The Company’s lead product candidate is termed Neuradiab. Neuradiab is a radiolabeled monoclonal antibody, which targets a certain protein expressed on 99% of GBM cells, but not on normal brain cells. As of December 31, 2008, the Company has not earned revenues from its drug candidates and is therefore considered to be in the development stage. During the year ended December 31, 2008, Bradmer worked with clinical investigators in the United States and the Food and Drug Administration (FDA) to construct a multi-center Phase III trial for the adjuvant use of Neuradiab in the management of GBM.